Search

Search Results

• Serious Adverse Events in Hematopoietic Stem Cell Donors: A Literature Review

  Elena Vitalevna Kuzmich, I.E. Pavlova, T.V. Glazanova, L.N. Bubnova

  327-334

  01.07.2026

• Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice

  Anastasiya Aleksandrovna Semenova, G.S. Tumyan, Yu.V. Ermakova, A.S. Chuprakova, A.P. Chernova, M.V. Frolova, N.B. Mikhailova, L.V. Fedorova, O.D. Serdyuk, S.V. Samarina, N.V. Nikolaeva, I.B. Lysenko, L.F. Mukharlyamova, G.N. Khusainova, N.V. Medvedeva, Ya.K. Mangasarova, A.Yu. Kuvshinov, D.V. Zaytsev, E.V. Karyagina, V.V. Denisova, T.I. Pospelova, I.N. Nechunaeva, K.S. Dedyukhina, N.G. Gabeeva, E.E. Zvonkov, A.D. Vorobev, O.S. Samoilova, I.V. Poddubnaya, Yu.V. Batukhtina, R.A. Zukov, E.N. Babich, T.N. Aleksandrova, I.S. Verkhoglyad, N.N. Glonina, I.Yu. Kudinova, E.A. Ukrainchenko, T.M. Sycheva, N.G. Ipatova, A.V. Proidakov, V.S. Morozov, G.Yu. Vyskub, V.V. Kobzev, E.V. Anikina, T.I. Ksenzova, Ya.V. Belenkaya, N.O. Zemlyakov

  241-252

  01.07.2026

• Pregnancy Management in Patients with Ph-Negative Myeloproliferative Neoplasms: A Literature Review and Case Report

  Kristina Teimurazovna Poghosyan, A.L. Melikyan, E.A. Gilyazitdinova, I.N. Subortseva, Z.V. Tratsevskaya, E.S. Polushkina, E.E. Sudneva, E.A. Kitsenko

  220-228

  01.04.2026

• Efficacy and Tolerability of the PET-Guided Program BrECADD for Advanced Stages of Classical Hodgkin Lymphoma: Data from the Real-World Setting in Russia

  Elena Andreevna Demina, O.S. Samoilova, A.V. Halturin, O.M. Malchuk, V.O. Sarzhevskiy, A.A. Samoylova, G.S. Tumyan, A.A. Semenova, A.F. Saidullaeva, K.D. Kaplanov, N.E. Mochkin, N.S. Shorokhov, Yu.V. Protopopova, V.Ya. Melnichenko

  172-179

  01.04.2026

• Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review

  K.S. Samarina, Yuliana Yurevna Assesorova, I.V. Berger

  162-171

  01.04.2026

• Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program

  Liudmila Valerevna Fedorova, N.B. Mikhailova, K.V. Lepik, A.M. Chekalov, O.G. Smykova, V.V. Markelov, G.S. Tumyan, A.A. Semenova, A.V. Arakelyan, L.S. Butaev, Iu.A. Oleinik, V.V. Ptushkin, Ya.K. Mangasarova, A.U. Magomedova, E.S. Gitelzon, N.G. Gabeeva, D.A. Koroleva, A.K. Smolianinova, E.E. Zvonkov, Iu.S. Osipov, N.V. Stepanova, T.V. Krinitsina, Yu.I. Podmankova, G.N. Khusainova, L.F. Mukharlyamova, O.R. Smirnova, I.V. Ishmatova, A.A. Zverkova, S.S. Elkhova, S.A. Volchenkov, I.S. Zyuzgin, D.D. Ivanova, E.A. Baryakh, E.N. Misyurina, P.A. Zeinalova, F.M. Abbasbeyli, O.L. Timofeeva, Yu.E. Ryabukhina, M.A. Ulyanova, V.V. Basmanova, T.N. Tsyganok, V.Yu. Kimaikina, S.V. Samarina, E.V. Zubkova, S.V. Ovanesyan, A.I. Iskhakova, A.Yu. Kuvshinov, A.A. Kuzyaeva, G.K. Isaeva, M.I. Andrievskikh, O.Yu. Arzhanukhina, T.V. Shelekhova, I.V. Morozova, P.V. Makarovskaya, O.S. Samoilova, I.V. Vasileva, A.Yu. Terekhova, N.A. Falaleeva, V.A. Shuvaev, S.V. Vlasova, V.A. Lapin, V.I. Bakhtina, A.D. Kulagin

  180-190

  01.04.2026

• Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA)

  T.V. Shelekhova, J. Kumar, S.J. Apte, Iu.S. Osipov, E.N. Misyurina, V.A. Doronin, T.S. Konstantinova, B.A. Bakirov, A.V. Proidakov, A.L. Uss, M. Kumar, E.V. Martynova, N.G. Chernova, M.A. Khokhar, A.D. Garifullin, C.R. Ross, S.L. Cyriac, S.V. Voloshin, M.A. Ulyanova, N.A. Falaleeva, N.A. Katin, D.V. Kirtbaya, M.O. Kiseleva, E.Yu. Komarceva, A.A. Myasnikov, D.K. Novik, M. Shabbir-Moosajee, S.V. Samarina, V.V. Denisova, G.N. Khusainova, T.K. Dolai, B. Bagchi, I.S. Zyuzgin, I.S. Moiseev, T.I. Pospelova, A.A. Semenova, M.A. Novikova, I.L. Davydkin, M.V. Kosinova, A.M. Pavlova, N. Sidharthan, H. Mukhopadhyay, A. Wahid, Q.M. Buttar, Yu.N. Linkova, A.V. Zinkina-Orikhan, Svyatoslav Vladimirovich Nechaev, A.S. Shadrina, A.A. Lutckii, D.O. Liaptseva

  119-130

  01.04.2026

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, E.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• Quality of Life and Symptom Profile in Polycythemia Vera Patients on Ruxolitinib Therapy in a Real-World Setting: Results of a Multi-Center Prospective Observational Study

  T.I. Ionova, Tatyana Pavlovna Nikitina, A.V. Proidakov, E.V. Lyurova, E.M. Volodicheva, L.A. Mkhitaryan, Yu.P. Martinova, T.V. Chitanava, N.B. Esefeva, M.O. Ivanova, T.I. Pospelova, A.S. Lyamkina, E.A. Knyazeva, E.G. Lomaia, N.S. Lazorko, K.P. Novoselov, D.A. Lipatova, N.M. Porfirieva, A.D. Kulagin

  14-26

  01.01.2026

• Efficacy and Safety of Ruxolitinib in Primary Myelofibrosis Patients with Abdominal Thrombotic Complications: A Case Series

  Yu.P. Martinova, E.V. Borovitskaya, S.S. Lebedeva, E.R. Efimova, O.E. Filippova, K.M. Chernysh, A.P. Smaglyuk, L.I. Napso, N.V. Novospasskaya, L.V. Kucheryavykh, Tamara Vangelevna Chitanava

  250-256

  01.07.2025

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease

  Sergei Vyacheslavovich Semochkin, E.I. Zhelnova, V.I. Kazey, A.V. Cherkasova, A.G. Nikiforova, N.F. Frolova, E.A. Baryakh, K.V. Yatskov, E.A. Karimova, O.N. Kotenko, E.N. Misyurina

  360-369

  01.10.2024

• Cardiovascular Toxicity of CAR-T Cell Therapy: A Literature Review

  Shakhabutdin Murtuzalievich Murtuzaliev, E.Yu. Salakheeva, S.A. Kardovskaya, Yu.Yu. Kirichenko, E.A. Siderko, Yu.N. Belenkov, I.S. Ilgisonis

  404-414

  01.10.2024

• Treatment Outcomes in Primary Mediastinal Large B-Cell Lymphoma. Experience of the AF Tsyb Medical Radiological Research Center (Obninsk)

  Alena Yurevna Terekhova, N.A. Falaleeva, A.B. Galitsyna, A.M. Chelmakov, A.A. Vovchenko, N.A. Riabikina, A.A. Danilenko, T. I. Bogatyreva

  225-236

  01.07.2024

• The Role of Polymorphic Variants of Р450 Cytochrome Genes as well as Genes GSTP1 and MDR1 in Toxic Complications of Program Drug Chemotherapy for Classical Hodgkin Lymphoma

  Yana Yurevna Shebunyaeva

  141-153

  01.04.2024

• Supportive Therapy in Multiple Myeloma: Practical Recommendations

  Maksim Valerevich Solovev, M.V. Soloveva, L.P. Mendeleeva

  426-448

  28.09.2023

• Cardiovascular Complications of the Immunotherapy of Hematological Malignancies: A Literature Review

  Geliya Rifkatovna Gimatdinova, O.E. Danilova, V.P. Kuzmin, G.I. Davydkin, Yu.V. Kostalanova, D.A. Kudlai, I.L. Davydkin

  407-412

  28.09.2023

• Nivo-BeGEV as Preparation for Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Study

  Yana Konstantinovna Mangasarova, T.N. Moiseeva, O.V. Margolin, L.G. Gorenkova, E.S. Nesterova, F.E. Babaeva, M.O. Bagova, E.A. Fastova, R.R. Abdurashidova, L.S. Al-Radi, E.I. Dorokhina, E.M. Volodicheva, V.A. Lapin, O.S. Samoilova, S.K. Kravchenko, A.U. Magomedova, E.E. Zvonkov

  280-286

  09.06.2023

• New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review

  O.E. Danilova, Geliya Rifkatovna Gimatdinova, I.L. Davydkin, O.V. Tereshina, V.D. Sabanova, G.I. Davydkin

  331-336

  09.06.2023

• Quality of Life Changes in Patients with Chronic Immune Thrombocytopenia in the Process of Romiplostim Therapy, its Efficacy and Safety in the Real-World Setting: Results of a Multi-Center Observational Study

  T.I. Ionova, O.Yu. Vinogradova, T.V. Shelekhova, D.G. Sherstnev, A.V. Proidakov, E.V. Lyyurova, M.M. Pankrashkina, L.A. Mukha, E.E. Markova, N.V. Novitskaya, T.I. Pospelova, T.N. Babaeva, N.B. Bulieva, G.B. Kuchma, E.A. Andreevskaya, E.E. Zinina, M.V. Frolova, K.B. Trizna, I.L. Shestopalova, T.V. Shneider, S.A. Volkova, S.G. Zakharov, I.I. Mulina, I.E. Solov’eva, A.A. Myasnikov, A.A. Kuchin, L.B. Khvorostenko, N.M. Porfirieva, Tatyana Pavlovna Nikitina, V.V. Ptushkin, S.V. Gritsaev

  154-165

  03.03.2023

• Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies

  A.A. Petrenko, Mariya Igorevna Kislova, E.A. Dmitrieva, E.A. Nikitin, V.V. Ptushkin

  37-45

  01.01.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Efficacy and Safety of Pola-BR Combination in Relapsed/Refractory Aggressive В-Cell Non-Hodgkin’s Lymphomas: A Russian Multi-Center Study

  Olesya Gennadevna Smykova, A.A. Semenova, Yu.B. Chernykh, T.A. Mitina, A.V. Kildyushevskii, S.K. Kravchenko, A.E. Misyurina, A.U. Magomedova, E.A. Baryakh, S.V. Samarina, N.P. Volkov, V.V. Markelov, P.V. Kotselyabina, L.V. Fedorova, K.V. Lepik, E.V. Kondakova, L.V. Stelmakh, V.V. Baykov, N.B. Mikhailova, I.S. Moiseev, G.S. Tumyan, E.A. Osmanov, A.D. Kulagin

  232-239

  01.07.2022

• Quality of Life and Efficacy of Triplet IxaRd Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Multi-Center Pilot Real-World Study

  T.I. Ionova, O.Yu. Vinogradova, Yu.B. Kochkareva, E.E. Markova, K.D. Kaplanov, M.N. Shirokova, T.V. Shelekhova, A.N. Levanov, A.V. Kopylova, O.Yu. Li, T.A. Mitina, O.A. Rukavitsyn, P.I. Simashova, L.V. Anchukova, E.N. Babich, S.A. Volkova, D.B. Dasheeva, M.V. Demchenkova, S.K. Dubov, T.V. Esenina, L.E. Ivanova, T.L. Kravchuk, E.V. Rimashevskaya, M.T. Savinova, N.O. Saraeva, N.M. Porfirieva, Tatyana Pavlovna Nikitina, V.V. Ptushkin

  240-252

  01.07.2022

• Pharmacoeconomic Analysis of CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemias

  Irina Vladimirovna Gribkova, A.A. Zavyalov

  205-212

  01.04.2022

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice

  T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasilev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfireva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova, D.G. Sherstnev

  42-53

  01.01.2022

• Carmustine in the Therapy of B-Cell Lymphomas

  Daria Aleksandrovna Koroleva, E.E. Zvonkov

  496-502

  01.10.2021

• Efficacy, Safety, and Tolerance of Gemtuzumab Ozogamicin Combined with FLAG/FLAG-Ida or Azacitidine in Relapsed/Refractory Acute Myeloblastic Leukemia

  Irina Garmaevna Budaeva, D.V. Zaitsev, A.A. Shatilova, E.N. Tochenaya, A.V. Petrov, R.I. Vabishchevich, D.V. Motorin, R.Sh. Badaev, D.B. Zammoeva, V.V. Ivanov, S.V. Efremova, K.V. Bogdanov, Yu.V. Mirolyubova, T.S. Nikulina, Yu.A. Alekseeva, A.Yu. Zaritskey, L.L. Girshova

  299-307

  01.07.2021

• Current Issues of Targeted Therapy of Polycythemia Vera

  Anait Levonovna Melikyan, I.N. Subortseva

  355-360

  01.07.2021

• Cardio-oncology and Oncohematology: Examination Algorithms, Prophylactic and Treatment of Cardiotoxicity, Trends in Rehabilitation

  Elena Ivanovna Emelina, G.E. Gendlin, I.G. Nikitin

  239-261

  01.04.2021

• Stable Chronology of Granulopoiesis under R(G)-DHAP Immunochemotherapy-Induced Cytotoxic Stress in Non-Hodgkin’s Lymphomas

  Kseniya Andreevna Sychevskaya, S.K. Kravchenko, F.E. Babaeva, A.E. Misyurina, A.M. Kremenetskaya, A.I. Vorob’ev

  204-219

  01.04.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• Checkpoint Inhibitors and Classical Hodgkin’s Lymphoma: Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Tumor (Experience at the NI Pirogov Russian National Medical Center of Surgery)

  Vladislav Olegovich Sarzhevskii, E.A. Demina, N.E. Mochkin, A.A. Spornik, A.A. Mamedova, E.G. Smirnova, A.E. Bannikova, A.A. Samoilova, V.S. Bogatyrev, V.Ya. Melnichenko

  53-62

  01.01.2021

• The Use of Checkpoint Inhibitors in Classical Hodgkin’s Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center’s Experience)

  Vladislav Olegovich Sarzhevskii, E.A. Demina, N.E. Mochkin, A.A. Spornik, A.A. Mamedova, E.G. Smirnova, A.E. Bannikova, A.A. Samoilova, V.S. Bogatyrev, O.Yu. Bronov, Yu.A. Abovich, V.Ya. Melnichenko

  307-315

  01.07.2020

• Long-Term Outcomes of Nivolumab Therapy in Patients with Relapsed/Refractory Classic Hodgkin’s Lymphoma after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Real Clinical Practice

  Kirill Viktorovich Lepik, N.P. Volkov, N.B. Mikhailova, E.V. Kondakova, L.A. Tsvetkova, Yu.R. Zalyalov, E.E. Lepik, L.V. Fedorova, A.V. Beinarovich, M.V. Demchenkova, O.G. Smykova, P.V. Kotselyabina, I.S. Moiseev, V.V. Baikov, B.V. Afanasyev

  280-288

  01.07.2020

• Pharmacokinetics, Safety, and Tolerance of Anagrelide, the First Domestic Generic, Compared with Reference Drug

  S.K. Zyryanov, V.V. Chistyakov, Olga Igorevna Butranova, E.S. Stepanova, O.G. Potanina, R.A. Abramovich

  346-353

  01.07.2020

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma

  Stanislav Semenovich Bessmeltsev, E.V. Karyagina, E.Yu. Ilyushkina, Zh.L. Stolypina, R.R. Miftakhova, I.I. Kostroma, T.L. Shelkovskaya

  25-32

  01.01.2020

• Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial

  Sergei Nikolaevich Bondarenko, E.N. Parovichnikova, A.A. Maschan, O.Yu. Baranova, T.V. Shelekhova, V.A. Doronin, V.Ya. Mel’nichenko, K.D. Kaplanov, O.S. Uspenskaya, A.N. Sokolov, N.V. Myakova, I.S. Moiseev, I.V. Markova, E.I. Darskaya, A.G. Smirnova, T.A. Bykova, B.I. Ayubova, I.A. Samorodova, E.V. Babenko, I.M. Barkhatov, T.L. Gindina, A.D. Kulagin, B.V. Afanas’ev

  145-153

  01.04.2019